Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17484615 | 0.86 | PPARA (0.42) | FFAR4FFAR1PPARAPPARDGPR3 | |
| SCHEMBL24313612 | 0.82 | L3MBTL1 (0.47) | GPR3 | |
| SCHEMBL5785776 | 0.77 | FFAR1 (0.50) | FFAR1MRGPRX4SLC6A4 | |
| SCHEMBL25354042 | 0.77 | PPARD (0.51) | FFAR4FFAR1PPARAPPARDMRGPRX4 | |
| SCHEMBL6417045 | 0.76 | GPR3 (0.42) | GPR3SCN5A | |
| SCHEMBL6207509 | 0.74 | TACR1 (0.41) | GPR3SLC6A4SCN8ASCN10A | |
| SCHEMBL4465407 | 0.73 | PPARA (0.50) | FFAR4FFAR1PPARAPPARDMRGPRX4 | |
| SCHEMBL17959897 | 0.73 | MRGPRX4 (0.42) | FFAR1MRGPRX4SCN10A | |
| SCHEMBL22714098 | 0.73 | GPR3 (0.48) | GPR3CYP2C9SCN5A | |
| SCHEMBL6412351 | 0.72 | BCHE (0.42) | FFAR4FFAR1PPARAPPARDGPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551836-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004031190-A1 | AZABICYCLIC AMINE DERIVATIVES AS NK-1 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-6555552-B2 | Psychological disorders; analgesics; antiinflammatory agents | MERCK SHARP & DOHME LTD. (GB) | 2003-04-29 | — | — | US | disclosed |
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147212-A1 | Azabicyclic amine derivatives and their use as therapeutic agents | CXCR1, CXCR6, CCR6 | FFAR4 492/4885FFAR1 331/4885PPARA 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.